Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
8.10
-0.24 (-2.88%)
At close: May 28, 2025, 4:00 PM
8.02
-0.08 (-0.95%)
After-hours: May 28, 2025, 5:14 PM EDT
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
170.39M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | - | - | - |
Mar 31, 2023 | - | - | - |
Mar 31, 2022 | - | - | - |
Mar 31, 2021 | 864.00K | - | - |
Mar 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CYBN News
- 6 days ago - Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025 - Business Wire
- 8 days ago - Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics - Business Wire
- 13 days ago - Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
- 14 days ago - Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase - Business Wire
- 20 days ago - Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder - Business Wire
- 27 days ago - Cybin to Participate at the 28th Annual Milken Institute Global Conference - Business Wire
- 5 weeks ago - Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - Business Wire
- 5 weeks ago - Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - Business Wire